Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459489 | 0.74 | ALDH1A1 (0.41) | HSD17B10TSHROPRM1MPOPOLB | |
| SCHEMBL8283007 | 0.74 | CHRM2 (0.41) | TSHRCHRM2CHRM3 | |
| SCHEMBL8282199 | 0.73 | PIK3CD (0.38) | TSHRCHRM2CHRM3POLB | |
| SCHEMBL16038492 | 0.73 | CHRM2 (0.36) | TSHRCHRM2CHRM3 | |
| SCHEMBL21389276 | 0.73 | CHRM2 (0.36) | TSHRCHRM2CHRM3 | |
| SCHEMBL15423533 | 0.72 | PLA2G7 (0.54) | OPRM1MPO | |
| SCHEMBL26684109 | 0.72 | POLB (0.44) | HSD17B10TSHROPRM1MPOPOLB | |
| SCHEMBL10159565 | 0.72 | HSD17B10 (0.41) | USP2HSD17B10TSHROPRM1MPO | |
| SCHEMBL15112875 | 0.71 | POLB (0.53) | TSHRPOLB | |
| SCHEMBL14359588 | 0.70 | HTR1A (0.36) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | USP2 3310/4885HSD17B10 293/4885TSHR 4413/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | USP2 3310/4885HSD17B10 293/4885TSHR 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.